Chronic Hepatitis B and Hepatocarcinogenesis: Does Prevention of “Collateral Damage” Bring the Cure?

This publication has 17 references indexed in Scilit:

• Prevention of Hepatocellular Carcinoma Development Associated with Chronic Hepatitis by Anti-Fas Ligand Antibody Therapy
  The Journal of Experimental Medicine, 2002
• Depletion of neutrophils blocks the recruitment of antigen-nonspecific cells into the liver without affecting the antiviral activity of hepatitis B virus-specific cytotoxic T lymphocytes
  Proceedings of the National Academy of Sciences, 2002
• Noncytolytic Control of Viral Infections by the Innate and Adaptive ImmuneResponse
  Annual Review of Immunology, 2001
• Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study
  Journal of Clinical Apheresis, 2001
• Chemokines
  Immunity, 2000
• Viral Clearance Without Destruction of Infected Cells During Acute HBV Infection
  Science, 1999
• Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand
  Nature Medicine, 1998
• Lymphocyte apoptosis induced by CD95 (APO–1/Fas) ligand–expressing tumor cells — A mechanism of immune evasion?
  Nature Medicine, 1996
• Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.
  The Journal of Experimental Medicine, 1993
• Hepatitis C-Related Hepatocellular Carcinoma
  Archives of internal medicine (1960), 1993